CARLSBAD, Calif., Jan. 2 /PRNewswire/ -- AviaraDx, Inc., a leader in molecular cancer profiling, announced today the appointment of Carol Berry as Vice President of Sales. Ms. Berry has extensive experience in sales leadership as well as commercializing innovative esoteric laboratory tests. She has been responsible for the North American sales and corporate marketing at Ciphergen Biosystems, Dynacare Laboratories, Cerner Corporation, and Roche Biomedical Laboratories. Ms. Berry holds an MBA degree from University of Dallas and an undergraduate degree from Texas A&M University.
"We are pleased that Carol joins us at such an important stage of the company's development," says Antonius Schuh, Ph.D., CEO of AviaraDx. "With laboratory tests based on our Molecular Cancer Identification (MCID) technology available through Quest Diagnostics, US Labs and Esoterix, and with the launch by Quest of a laboratory developed test based on our Breast Cancer Profiling (BCP) technology, Carol's extensive knowledge in the commercialization and medical adoption of innovative diagnostic tests will be essential for our success in the market."
"I am very impressed by the advanced stage of AviaraDx's molecular cancer profiling technologies and the significant need in the market for its two leading technology offerings, MCID and BCP," said Carol Berry. "Today, 25% of all metastatic tumor patients do not receive a sufficient classification of their cancer type, making treatment decisions challenging. The MCID technology is a powerful tool to address this problem. The company's BCP technology identifies ER+ breast cancer patients with dysfunctional estrogen signaling, resulting in inferior patient prognosis. There is tremendous potential for generating near term revenues through AviaraDx's business model which utilizes national and international licensees as distribution channels. In addition, the company expects to serve customers directly through its own laboratory operations in the near future."
About AviaraDx, Inc.
AviaraDx, Inc. is focused on developing and commercializing molecular diagnostic technologies for personalized medicine in cancer treatment. The company is targeting the oncology market with three first-in-class molecular cancer profiling technologies: Molecular Cancer Identification (MCID), Breast Cancer Profiling (BCP) and Drug Response Profiling (DRP). AviaraDx has licensed its technologies for specific clinical indications to reference laboratories in the United States and Europe. Please visit the AviaraDx website at https://www.aviaradx.com for more information.
Source: AviaraDx, Inc.